Marker Therapeutics, Inc.
MRKRNasdaq
$1.31
↓ -2.2%Jul 17 close · end-of-day
Price
1Y↓ -18.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.3M
Enterprise Value
$10.4M
P/E
—
P/S
6.4
P/B
1.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3.9M
Net Income (TTM)
-$10.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-304.0%
Net Margin
-275.9%
ROE
-79.0%
ROIC
—
Debt / Equity
—
Net Cash
$14.9M
Return 1Y
-31.8%
Company profile
Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.
- CEO
- Peter L. Hoang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Texas
- Website
- markertherapeutics.com
Earnings
MRKR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$751,691.00↑ +115.3%
Diluted EPS-$0.16↓ -60.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $500,000.00 | $0.00 | $3.5M | $3.3M | $6.6M | $3.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$28.9M | -$39.5M | -$19.8M | -$14.6M | -$11.1M | -$12.9M |
| Net income | -$28.7M | -$41.9M | -$29.9M | -$8.2M | -$10.7M | -$12.2M |
| Diluted EPS | -$0.61 | -$5.47 | -$3.58 | -$0.94 | -$1.19 | -$0.79 |
| Operating cash flow | -$20.0M | -$27.3M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -5777.2% | — | -563.3% | -440.4% | -168.7% | -363.5% |
| Net margin | -5741.2% | — | -851.9% | -248.8% | -162.8% | -343.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.9M | $2.3M | $349,104.00 | $861,184.00 | $1.2M | $1.1M | $751,691.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.3M | -$2.4M | -$3.9M | -$5.0M | -$4.3M | -$2.1M | -$1.5M | -$4.1M |
| Net income | -$2.2M | -$2.3M | -$3.8M | -$4.4M | -$4.0M | -$2.0M | -$1.7M | -$3.2M |
| Diluted EPS | -$0.25 | -$0.26 | -$0.41 | -$0.40 | -$0.29 | -$0.12 | $0.02 | -$0.16 |
| Operating cash flow | -$3.6M | $1.2M | -$4.7M | -$5.5M | -$1.9M | -$2.7M | -$1.9M | -$1.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -197.4% | -124.6% | -171.5% | -1420.1% | -494.8% | -173.3% | -139.1% | -541.8% |
| Net margin | -187.5% | -119.8% | -170.4% | -1273.6% | -466.3% | -162.1% | -154.4% | -423.0% |
Company news
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.